Altimmune, Inc. (ALT) Misses Q4 EPS by 10c

Altimmune, Inc. (NASDAQ: ALT) reported Q4 EPS of ($0.54), $0.10 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $37 thousand versus the consensus estimate of $2.14 thousand.

For earnings history and earnings-related data on Altimmune, Inc. (ALT) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• United Community Banks sells equipment finance unit for $1.9 billion
• UBS Reiterates Neutral Rating on Clorox (CLX) as External Challenges Persist